牛牛AI助理已提取核心訊息
Jin Medical International Ltd. has announced that it has regained compliance with the Nasdaq's minimum public holder requirement, as per the Nasdaq Listing Rule 5550(a)(3). The company had previously been notified of non-compliance on September 25, 2023, due to having fewer than the required 300 public holders. After failing to provide a detailed compliance plan, Jin Medical International faced potential delisting and requested a hearing with the Nasdaq Hearings Panel. The delisting was stayed pending a decision from the Panel, with a hearing scheduled for March 14, 2024. On February 29, 2024, the company was informed of its regained compliance status. However, Jin Medical International still faces an outstanding issue due to not filing its annual report on Form 20-F for the period ended September 30, 2023. The scheduled hearing will address this remaining deficiency. The company is actively working on remedial actions to comply with the periodic filing requirements.
Jin Medical International Ltd. has announced that it has regained compliance with the Nasdaq's minimum public holder requirement, as per the Nasdaq Listing Rule 5550(a)(3). The company had previously been notified of non-compliance on September 25, 2023, due to having fewer than the required 300 public holders. After failing to provide a detailed compliance plan, Jin Medical International faced potential delisting and requested a hearing with the Nasdaq Hearings Panel. The delisting was stayed pending a decision from the Panel, with a hearing scheduled for March 14, 2024. On February 29, 2024, the company was informed of its regained compliance status. However, Jin Medical International still faces an outstanding issue due to not filing its annual report on Form 20-F for the period ended September 30, 2023. The scheduled hearing will address this remaining deficiency. The company is actively working on remedial actions to comply with the periodic filing requirements.
Jin Medical International Ltd.宣佈，根據納斯達克上市規則5550（a）（3），它已重新遵守納斯達克的最低公衆持有人要求。該公司此前曾在2023年9月25日收到違規通知，原因是公衆持有人少於規定的300人。由於未能提供詳細的合規計劃，Jin Medical International可能面臨退市，並要求與納斯達克聽證會小組舉行聽證會。在專家小組做出決定之前，暫緩除名，聽證會定於2024年3月14日舉行。2024年2月29日，該公司被告知其恢復了合規狀態。但是，由於沒有提交截至2023年9月30日的20-F表年度報告，金醫療國際仍然面臨一個懸而未決的問題。預定的聽證會將解決這一剩餘的缺陷。該公司正在積極採取補救措施，以遵守定期申報要求。
Jin Medical International Ltd.宣佈，根據納斯達克上市規則5550（a）（3），它已重新遵守納斯達克的最低公衆持有人要求。該公司此前曾在2023年9月25日收到違規通知，原因是公衆持有人少於規定的300人。由於未能提供詳細的合規計劃，Jin Medical International可能面臨退市，並要求與納斯達克聽證會小組舉行聽證會。在專家小組做出決定之前，暫緩除名，聽證會定於2024年3月14日舉行。2024年2月29日，該公司被告知其恢復了合規狀態。但是，由於沒有提交截至2023年9月30日的20-F表年度報告，金醫療國際仍然面臨一個懸而未決的問題。預定的聽證會將解決這一剩餘的缺陷。該公司正在積極採取補救措施，以遵守定期申報要求。
有用
沒用